Free Trial

This company has been marked as potentially delisted and may not be actively trading.

BeiGene (BGNE) Stock Forecast & Price Target

BeiGene logo
Get the Latest News and Ratings for BGNE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BeiGene and its competitors.

Sign Up

BGNE Analyst Ratings Over Time

TypeCurrent Forecast
4/25/24 to 4/25/25
1 Month Ago
3/26/24 to 3/26/25
3 Months Ago
1/26/24 to 1/25/25
1 Year Ago
4/26/23 to 4/25/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
8 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$253.92$240.64$253.69$250.13
Forecasted UpsideN/A30.28% Upside37.34% Upside68.37% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

BGNE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BGNE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BeiGene Stock vs. The Competition

TypeBeiGeneMedical CompaniesS&P 500
Consensus Rating Score
2.83
2.82
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted UpsideN/A2,776.73% Upside21.29% Upside
News Sentiment Rating
Neutral News

See Recent BGNE News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/3/2024Morgan Stanley
3 of 5 stars
 Reiterated RatingOverweight$300.00+45.81%
11/13/2024TD Cowen
4 of 5 stars
 Boost TargetBuy ➝ Buy$254.00 ➝ $260.00+32.21%
10/22/2024JPMorgan Chase & Co.
2 of 5 stars
 Boost TargetOverweight ➝ Overweight$200.00 ➝ $235.00+7.12%
9/18/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Benjamin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Outperform$288.00+45.82%
8/8/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$269.00 ➝ $288.00+57.06%
7/9/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$180.00 ➝ $152.50+5.82%
3/27/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform ➝ Market Perform$196.00 ➝ $161.00+4.67%
2/27/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$350.00 ➝ $345.00+98.62%
9/12/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$259.00+25.82%
9/11/2023Macquarie
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$259.00+23.78%
8/17/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$287.00+49.22%
6/30/202351job
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingDowngrade
6/30/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingDowngrade
6/30/20233M
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingDowngrade

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:39 AM ET.


Should I Buy BeiGene Stock? BGNE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 22, 2025. Please send any questions or comments about these BeiGene pros and cons to contact@marketbeat.com.

BeiGene
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in BeiGene, Ltd.:

  • The current stock price is around $191.78, which may present a buying opportunity for investors looking for growth in the biotech sector.
  • Recent short interest has increased, indicating that some investors are betting against the stock, which can lead to a short squeeze if the company performs well.
  • Institutional ownership is significant, with nearly 49% of shares held by institutional investors, suggesting confidence in the company's future prospects.
  • BeiGene, Ltd. has shown resilience in its stock performance, with a relatively stable average daily trading volume, indicating consistent investor interest.
  • The company has a strong pipeline of products, which could lead to future revenue growth and market expansion.

BeiGene
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in BeiGene, Ltd. for these reasons:

  • The stock has experienced a decline of about 5.4% over the past year, which may raise concerns about its performance in a competitive market.
  • Short interest has increased significantly, which could indicate negative sentiment among investors regarding the company's future performance.
  • With no float size reported, it may suggest limited liquidity, making it harder for investors to buy or sell shares without affecting the stock price.
  • The company has a high days-to-cover ratio, indicating that it may take longer for short sellers to cover their positions, which can lead to increased volatility.
  • Despite institutional ownership, the overall market sentiment may still be cautious, affecting stock performance in the near term.

BGNE Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for BeiGene is $253.92, with a high forecast of $300.00 and a low forecast of $152.50.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There is currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BGNE shares.

According to analysts, BeiGene's stock has a predicted upside of ∞ based on their 12-month stock forecasts.

Analysts like BeiGene more than other "medical" companies. The consensus rating score for BeiGene is 2.83 while the average consensus rating score for "medical" companies is 2.82. Learn more on how BGNE compares to other companies.


This page (NASDAQ:BGNE) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners